Skip to main content

Lybrel FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 22, 2007)
Brand name: Lybrel
Generic name: levonorgestrel and ethinyl estradiol
Dosage form: Tablets
Company: Wyeth Pharmaceuticals Inc.
Treatment for: Birth Control

Marketing Status: Discontinued

Lybrel (levonorgestrel and ethinyl estradiol) is a low-dose combination contraceptive pill taken continuously (without a pill-free interval) and over time may eliminate scheduled menstrual periods. Lybrel is indicated for the prevention of pregnancy.

Development timeline for Lybrel

DateArticle
May 23, 2007Approval FDA Approves Lybrel, First Low Dose Combination Oral ContraceptiveOffering Women the Opportunity to Be Period-Free Over Time
Jun 28, 2006Wyeth Receives Approvable Letter From the FDA for Lybrel
Jul 27, 2005Wyeth's New Drug Application for New Oral Contraceptive With Uninterrupted Dosing Regimen Accepted for Filing at FDA

See also

Lybrel (levonorgestrel and ethinyl estradiol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer